CU23833A3 - Anticuerpos antimesotelina - Google Patents
Anticuerpos antimesotelinaInfo
- Publication number
- CU23833A3 CU23833A3 CU2010000098A CU20100098A CU23833A3 CU 23833 A3 CU23833 A3 CU 23833A3 CU 2010000098 A CU2010000098 A CU 2010000098A CU 20100098 A CU20100098 A CU 20100098A CU 23833 A3 CU23833 A3 CU 23833A3
- Authority
- CU
- Cuba
- Prior art keywords
- antibodies
- antigen
- binding regions
- mesothelin
- disorders
- Prior art date
Links
- 102000003735 Mesothelin Human genes 0.000 abstract 2
- 108090000015 Mesothelin Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027406 Mesothelioma Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US437807P | 2007-11-26 | 2007-11-26 | |
| PCT/EP2008/009756 WO2009068204A1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23833A3 true CU23833A3 (es) | 2012-10-15 |
Family
ID=40351874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2010000098A CU23833A3 (es) | 2007-11-26 | 2010-05-21 | Anticuerpos antimesotelina |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9023351B2 (enExample) |
| EP (3) | EP2634196A1 (enExample) |
| JP (3) | JP5608091B2 (enExample) |
| KR (1) | KR101559599B1 (enExample) |
| CN (2) | CN104151429B (enExample) |
| AU (1) | AU2008329221B2 (enExample) |
| BR (1) | BRPI0819909B8 (enExample) |
| CA (1) | CA2706529C (enExample) |
| CO (1) | CO6280409A2 (enExample) |
| CR (1) | CR11456A (enExample) |
| CU (1) | CU23833A3 (enExample) |
| CY (1) | CY1117437T1 (enExample) |
| DK (1) | DK2215121T3 (enExample) |
| DO (1) | DOP2010000150A (enExample) |
| EC (1) | ECSP10010191A (enExample) |
| ES (1) | ES2569513T3 (enExample) |
| GT (1) | GT201000148A (enExample) |
| HN (1) | HN2010001062A (enExample) |
| HR (1) | HRP20160485T1 (enExample) |
| HU (1) | HUE027358T2 (enExample) |
| IL (1) | IL205681A0 (enExample) |
| MA (1) | MA31862B1 (enExample) |
| MX (1) | MX2010005603A (enExample) |
| MY (1) | MY157164A (enExample) |
| NZ (1) | NZ585551A (enExample) |
| PL (1) | PL2215121T3 (enExample) |
| SI (1) | SI2215121T1 (enExample) |
| TN (1) | TN2010000234A1 (enExample) |
| UA (1) | UA106036C2 (enExample) |
| WO (1) | WO2009068204A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2700860C (en) * | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| SI2215121T1 (sl) * | 2007-11-26 | 2016-06-30 | Bayer Intellectual Property Gmbh | Protitelesa anti-mezotelin in njihova uporaba |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US8911732B2 (en) * | 2010-12-20 | 2014-12-16 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| CN104955845B (zh) * | 2012-09-27 | 2018-11-16 | 美国政府(由卫生和人类服务部的部长所代表) | 间皮素抗体和引起有效的抗肿瘤活性的方法 |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| WO2015096982A1 (de) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Binder-konjugate (adcs) mit ksp-inhibitoren |
| CA2960925A1 (en) | 2014-09-30 | 2016-04-07 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| PT3298033T (pt) | 2015-05-18 | 2020-09-22 | Tcr2 Therapeutics Inc | Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão |
| MX392478B (es) | 2015-06-22 | 2025-03-24 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
| CN108025067A (zh) * | 2015-06-30 | 2018-05-11 | 汉霖生技股份有限公司 | 抗血管内皮生长因子受体2（vegfr2）抗体 |
| SG11201801351RA (en) * | 2015-08-21 | 2018-03-28 | Carsgen Therapeutics Ltd | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP4643874A2 (en) | 2015-12-22 | 2025-11-05 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| AU2016382512A1 (en) | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| WO2017141604A1 (ja) | 2016-02-15 | 2017-08-24 | 地方独立行政法人神奈川県立病院機構 | 膜型ムチン様タンパク質の認識とその医療応用 |
| JP2019513347A (ja) | 2016-03-04 | 2019-05-30 | ノバルティス アーゲー | 複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用 |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| SG10202008909VA (en) | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| IL312206A (en) | 2016-04-15 | 2024-06-01 | Novartis Ag | Preparations and methods for selective protein expression |
| KR20190014525A (ko) | 2016-05-27 | 2019-02-12 | 애브비 바이오테라퓨틱스 인크. | 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질 |
| US11001636B2 (en) | 2016-06-15 | 2021-05-11 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
| CA3047489A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| US20210079057A1 (en) | 2017-06-13 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| ES3024433T3 (en) | 2017-12-19 | 2025-06-04 | F Star Therapeutics Ltd | Fc binding fragments comprising a pd-l1 antigen-binding site |
| CN111511911B (zh) * | 2017-12-24 | 2023-11-03 | 诺伊尔免疫生物科技株式会社 | 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞 |
| WO2019210054A1 (en) | 2018-04-27 | 2019-10-31 | Biogen Ma Inc. | Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| IL280002B2 (en) | 2018-07-12 | 2025-05-01 | F Star Beta Ltd | Antibody molecules that bind CD137 and OX40 |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| EP3844192A1 (en) | 2018-08-30 | 2021-07-07 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN113226472B (zh) | 2018-12-17 | 2025-01-28 | 雷维托普有限公司 | 双免疫细胞衔接物 |
| CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| MX2021009764A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021011040A (es) * | 2019-03-14 | 2021-12-10 | Morphosys Ag | Anticuerpos dirigidos contra c5ar. |
| EA202192555A1 (ru) | 2019-03-19 | 2021-11-25 | Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн | Комбинированная терапия для лечения рака |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| US20220267437A1 (en) * | 2019-07-29 | 2022-08-25 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
| CN119684459A (zh) | 2019-12-20 | 2025-03-25 | 安进公司 | 治疗实体瘤的靶向间皮素的cd40激动性多特异性抗体构建体 |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN116063527A (zh) * | 2021-09-30 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向间皮素的抗体及其用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN120129696A (zh) | 2022-09-01 | 2025-06-10 | 乔治亚大学研究基金公司 | 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法 |
| CN120166937A (zh) | 2022-10-25 | 2025-06-17 | 佩普托米克公司 | 用于治疗癌症的联合疗法 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| CN120826416A (zh) * | 2022-12-02 | 2025-10-21 | 杰科生物医药公司 | 抗间皮素双特异性抗体及其使用方法 |
| CN121038806A (zh) | 2023-04-25 | 2025-11-28 | 阿森纳生物科学公司 | 用于转录调控的新颖受体 |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| TW202513088A (zh) | 2023-06-07 | 2025-04-01 | 瓦爾希伯倫私人腫瘤研究基金會 | 用於治療癌症的與ｍｅｋ抑制劑的組合療法 |
| WO2024251854A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with braf inhibitors for the treatment of cancer |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| EP0871492B1 (en) * | 1996-01-05 | 2003-11-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Mesothelium antigen and methods and kits for targeting it |
| ATE317437T1 (de) | 1997-12-01 | 2006-02-15 | Us Gov Health & Human Serv | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| CA2369433A1 (en) * | 1999-02-26 | 2000-08-31 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| AU781396B2 (en) | 1999-07-20 | 2005-05-19 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| WO2006124641A2 (en) * | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| CA2608498C (en) | 2005-05-18 | 2017-04-04 | Morphosys Ag | Anti-gm-csf antibodies and uses therefor |
| KR20080031001A (ko) * | 2005-06-02 | 2008-04-07 | 아스트라제네카 아베 | Ｃｄ20에 대한 항체 및 그의 용도 |
| CA2700860C (en) * | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| SI2215121T1 (sl) * | 2007-11-26 | 2016-06-30 | Bayer Intellectual Property Gmbh | Protitelesa anti-mezotelin in njihova uporaba |
-
2008
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en not_active Ceased
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko not_active Expired - Fee Related
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en not_active IP Right Cessation
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 HR HRP20160485TT patent/HRP20160485T1/hr unknown
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt not_active IP Right Cessation
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh not_active Expired - Fee Related
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja not_active Expired - Fee Related
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en not_active Ceased
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh not_active Expired - Fee Related
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
-
2018
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23833A3 (es) | Anticuerpos antimesotelina | |
| AR053608A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| CY1119051T1 (el) | Αντισωματα anti-c4.4a και χρησεις αυτων | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
| AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
| CL2017002345A1 (es) | Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| MX2015016814A (es) | Anticuerpo anti-tweakr y sus usos. | |
| ECSP11011423A (es) | Inmunoconjugados de antimesotelina y usos de los mismos | |
| BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
| BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
| AR088941A1 (es) | Anticuerpos anti-fgfr2 y sus usos | |
| AR104047A1 (es) | Anticuerpos anti-ceacam6 y sus usos | |
| EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
| SG142330A1 (en) | Anti-cd38 human antibodies and uses therefor | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| PL422231A1 (pl) | Komórki immunologiczne CAR do leczenia nowotworów | |
| PE20250392A1 (es) | Anticuerpos a la alfa-sinucleina y usos de los mismos | |
| EA201300470A1 (ru) | Антитела | |
| CL2009000567A1 (es) | Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer. | |
| CL2022002766A1 (es) | Anticuerpos anti-phf-pau y sus usos. | |
| CO6420322A2 (es) | Anticuerpos anti-mst1r y usos de los mismos | |
| AR051928A1 (es) | Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas | |
| BR112014024230A8 (pt) | Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |